{"title":"大麻与健康研究计划将帮助把药用大麻纳入医疗保健中","authors":"Johannes Thrul, Ryan Vandrey","doi":"10.1038/s41591-024-03288-w","DOIUrl":null,"url":null,"abstract":"<p>In the USA, there are more than 5.5 million registered patients in state-regulated medicinal cannabis programs and many people use hemp products (sourced from cannabis containing <0.3% delta-9-tetrahydrocannabinol (THC) by dry weight) for therapeutic purposes. However, clinical research on non-pharmaceutical cannabis products remains limited<sup>1</sup>, healthcare providers feel inadequately trained on integrating medicinal cannabis into their practice<sup>2</sup>, and medicinal cannabis use is poorly documented in electronic medical records (EMRs)<sup>3</sup>. These issues highlight the need for patient-level data on the impacts of medicinal cannabis use<sup>4</sup>.</p><p>With legalization of retail cannabis sales in some US states, the diversity of cannabis products available to consumers has substantially increased<sup>5</sup>. Products vary in chemical composition<sup>6</sup>, dose and intended route of administration, all of which can affect clinical effect, safety and abuse liability, and should be considered in clinical decision making. The diversity in cannabis products and the use of poorly defined nomenclature contributes to difficulty in assessing the health effects of medicinal cannabis.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"31 1","pages":""},"PeriodicalIF":58.7000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Cannabis and Health Research Initiative will help integrate medicinal cannabis in healthcare\",\"authors\":\"Johannes Thrul, Ryan Vandrey\",\"doi\":\"10.1038/s41591-024-03288-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>In the USA, there are more than 5.5 million registered patients in state-regulated medicinal cannabis programs and many people use hemp products (sourced from cannabis containing <0.3% delta-9-tetrahydrocannabinol (THC) by dry weight) for therapeutic purposes. However, clinical research on non-pharmaceutical cannabis products remains limited<sup>1</sup>, healthcare providers feel inadequately trained on integrating medicinal cannabis into their practice<sup>2</sup>, and medicinal cannabis use is poorly documented in electronic medical records (EMRs)<sup>3</sup>. These issues highlight the need for patient-level data on the impacts of medicinal cannabis use<sup>4</sup>.</p><p>With legalization of retail cannabis sales in some US states, the diversity of cannabis products available to consumers has substantially increased<sup>5</sup>. Products vary in chemical composition<sup>6</sup>, dose and intended route of administration, all of which can affect clinical effect, safety and abuse liability, and should be considered in clinical decision making. The diversity in cannabis products and the use of poorly defined nomenclature contributes to difficulty in assessing the health effects of medicinal cannabis.</p>\",\"PeriodicalId\":19037,\"journal\":{\"name\":\"Nature Medicine\",\"volume\":\"31 1\",\"pages\":\"\"},\"PeriodicalIF\":58.7000,\"publicationDate\":\"2024-10-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41591-024-03288-w\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41591-024-03288-w","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
The Cannabis and Health Research Initiative will help integrate medicinal cannabis in healthcare
In the USA, there are more than 5.5 million registered patients in state-regulated medicinal cannabis programs and many people use hemp products (sourced from cannabis containing <0.3% delta-9-tetrahydrocannabinol (THC) by dry weight) for therapeutic purposes. However, clinical research on non-pharmaceutical cannabis products remains limited1, healthcare providers feel inadequately trained on integrating medicinal cannabis into their practice2, and medicinal cannabis use is poorly documented in electronic medical records (EMRs)3. These issues highlight the need for patient-level data on the impacts of medicinal cannabis use4.
With legalization of retail cannabis sales in some US states, the diversity of cannabis products available to consumers has substantially increased5. Products vary in chemical composition6, dose and intended route of administration, all of which can affect clinical effect, safety and abuse liability, and should be considered in clinical decision making. The diversity in cannabis products and the use of poorly defined nomenclature contributes to difficulty in assessing the health effects of medicinal cannabis.
期刊介绍:
Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors.
Nature Medicine consider all types of clinical research, including:
-Case-reports and small case series
-Clinical trials, whether phase 1, 2, 3 or 4
-Observational studies
-Meta-analyses
-Biomarker studies
-Public and global health studies
Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.